良性肾上腺意外瘤皮质醇分泌的时间变化与长期结局的关联:回顾性队列研究
该回顾性队列研究纳入2525例良性肾上腺意外瘤成人患者,评估重复1mg过夜地塞米松抑制试验(1-mg DST)结果变化与心代谢结局及死亡率的关联。
要点
- 校正年龄和心血管危险因素后,DST轨迹与死亡及心血管事件无独立关联。
核心结论
- 纵向1-mg DST变化常见,持续异常患者高血压恶化风险较高,但死亡率及心血管或血栓事件在校正年龄和心血管危险因素后与DST轨迹无显著独立关联。
研究设计与样本
- 回顾性队列研究,纳入欧洲14国25个肾上腺中心2000年1月1日至2020年12月1日诊断的良性肾上腺意外瘤成人患者,要求至少两次1-mg DST且随访至少36个月,共2525例,中位随访80个月(IQR 49-122)。
主要发现
- 持续异常组(MACS-to-MACS,n=839)较持续正常组(NFAT-to-NFAT,n=1103)年龄更大、心代谢负担更重。
- 粗分析中较高基线DST后皮质醇、较大累积皮质醇暴露及MACS-to-MACS与较短生存和无事件时间相关,但多变量校正后不独立于年龄和基线心代谢危险因素。
关键数值与推荐
- MACS定义为1-mg DST后皮质醇浓度高于50 nmol/L。
临床怎么用
- 对良性肾上腺意外瘤患者,重复1-mg DST可识别持续异常者,该群体心代谢风险高,应更密切关注可干预危险因素。
局限性
- 回顾性设计;校正年龄和心血管危险因素后关联不显著;需前瞻性研究确立重复1-mg DST对风险分层的临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mild autonomous cortisol secretion (MACS), the most common hormonal abnormality in adrenal incidentalomas, is associated with increased cardiometabolic risk. MACS is defined by cortisol concentrations higher than 50 nmol/L after a 1-mg overnight dexamethasone suppression test (1-mg DST). The prognostic value of a single test remains uncertain. We examined longitudinal changes in 1-mg DST results, cumulative cortisol exposure, and their associations with cardiometabolic outcomes and mortality. METHODS: In this retrospective cohort study conducted in 25 adrenal centres that are part of the European Network for the Study of Adrenal Tumours consortium across 14 countries with adults (aged ≥18 years) with benign adrenal incidentalomas diagnosed from Jan 1, 2000, to Dec 1, 2020, two or more 1-mg DSTs, and follow-up of at least 36 months, we used multivariable Cox models to assess associations between longitudinal 1-mg DST results and all-cause mortality and cardiovascular and thrombotic events. Patients with Cushing's syndrome, primary aldosteronism, phaeochromocytoma, or androgen-secreting tumour at baseline; active malignancy within 36 months of incidentaloma diagnosis; or suspicion of unreliable 1-mg DST results were excluded, along with patients taking oral glucocorticoids, strong CYP3A4 modulators, adrenal enzyme inhibitors, oral oestrogen, or selective oestrogen receptor modulators. Cumulative cortisol exposure was estimated from serial 1-mg DSTs. Restricted mean survival time (RMST) quantified differences in event-free time. Data were collected from the electronic health records of all eligible patients at each participating centre. FINDINGS: Among 2525 patients (median follow-up 80 months [IQR 49-122]), 563 (22·3%) had changes in 1-mg DST results leading to a change in diagnosis, most within 3 years of their baseline 1-mg DST. Patients with persistently abnormal 1-mg DST results (ie, MACS-to-MACS patients; n=839) were older and had a greater cardiometabolic burden than those with persistently normal results (ie, non-functioning adrenal tumours [NFAT]-to-NFAT patients; n=1103). MACS-to-MACS patients had a higher rate of worsening hypertension (adjusted hazard ratio 1·34 [95% CI 1·03-1·73]) and a shorter event-free time for worsening hypertension (10-year RMST 60·4 months [56·8-75·5] vs 86·1 months [79·1-93·4]) than NFAT-to-NFAT patients. In crude analyses, patients with higher baseline post-1-mg DST cortisol, patients with greater cumulative cortisol exposure, and MACS-to-MACS patients had shorter survival and event-free time; however, these associations were not independent of age and baseline cardiometabolic risk factors after multivariable adjustment. INTERPRETATION: Longitudinal 1-mg DST changes are common. MACS-to-MACS patients had worsening hypertension, but rates of mortality and cardiovascular or thrombotic events were not significantly associated with 1-mg DST trajectories after adjustment for age and cardiovascular risk factors. These findings identify patients with persistently abnormal 1-mg DST results as a group with high cardiometabolic risk that warrants closer attention to modifiable risk factors. Prospective studies are needed to establish the clinical significance of repeated 1-mg DSTs for risk stratification. FUNDING: National Institute for Health and Care Research Birmingham Biomedical Research Centre, Horizon Europe 2022, and Deutsche Forschungsgemeinschaft.
引用
- Suntornlohanakul O, Reimondo G, Ghislieri M, et al. Temporal changes in cortisol secretion and their association with long-term outcomes in benign adrenal incidentalomas: a retrospective cohort study. Lancet Diabetes Endocrinol. 2026. PMID: 42413529. doi:10.1016/S2213-8587(26)00098-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。